A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)

This study has been completed.
Sponsor:
Information provided by:
Genentech
ClinicalTrials.gov Identifier:
NCT00312728
First received: April 7, 2006
Last updated: August 3, 2011
Last verified: August 2011
  Purpose

This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated central nervous system (CNS) metastases. A total of 115 patients enrolled in the study.


Condition Intervention Phase
Non-Small Cell Lung Cancer
Brain Neoplasms
Drug: bevacizumab
Drug: First-Line Chemotherapy Agents
Drug: Second-Line Chemotherapy Agents
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Genentech:

Primary Outcome Measures:
  • Percentage of Participants With Symptomatic National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0 (NCI CTCAE) Grade ≥2 Central Nervous System (CNS) Hemorrhage [ Time Frame: From the first administration of bevacizumab until 60 days after discontinuation of bevacizumab treatment was reported (up to 2 years) ] [ Designated as safety issue: Yes ]

    The percentage of participants with symptomatic NCI CTCAE Grade ≥ 2 CNS hemorrhage, defined as the presence of clinical symptoms determined by the investigator to be directly referable to a Grade ≥ 2 CNS hemorrhage.

    Grade 1: Asymptomatic, radiographic findings only Grade 2: Medical intervention indicated Grade 3: Ventriculostomy, intracranial pressure (ICP) monitoring, intraventricular thrombolysis, or operative intervention indicated Grade 4: Life-threatening consequences; neurologic deficit or disability Grade 5: Death



Secondary Outcome Measures:
  • Overall Survival (OS) in First-line Setting [ Time Frame: Time from enrollment to death from any cause (up to 2 years) ] [ Designated as safety issue: No ]
    To assess overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.

  • Number of Participants With Overall Survival (OS) in First-line Setting [1−Year or More Survival] [ Time Frame: Time from enrollment to death from any cause (up to 2 years) ] [ Designated as safety issue: No ]
    Number of Participants with overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.

  • OS in First-line and Second-line Settings [ Time Frame: Time from enrollment to death from any cause (up to 2 years) ] [ Designated as safety issue: No ]
    To assess overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.

  • Number of Participants With OS in First-line and Second-line Settings [1−Year or More Survival] [ Time Frame: Time from enrollment to death from any cause (up to 2 years) ] [ Designated as safety issue: No ]
    To assess the number of participants with overall survival in the subset of subjects treated in the first-line setting with bevacizumab plus either chemotherapy or erlotinib for non-squamous NSCLC with previously treated brain metastases.

  • Number of Participants With Selected Adverse Events [ Time Frame: From start of bevacizumab treatment to 60 days following discontinuation of bevacizumab (up to 2 years) ] [ Designated as safety issue: No ]

    Number of participants with selected adverse events (all grades based on NCI CTCAE) included any grade CNS hemorrhage, any grade pulmonary hemorrhage, any grade gastrointestinal (GI) perforation, Grade ≥ 2 arterial thromboembolic event, Grade ≥ 2 left ventricular systolic dysfunction, Grade ≥ 3 non-CNS non-pulmonary hemorrhage, Grade ≥ 3 proteinuria, Grade ≥ 3 proteinuria, Grade ≥ 3 hypertension, any serious adverse event*, and any adverse event leading to study treatment discontinuation.

    *For serious adverse events, please see Adverse Event Reporting Section.



Enrollment: 115
Study Start Date: March 2006
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: bevacizumab Drug: bevacizumab
15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be < 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
Other Name: Avastin
Drug: First-Line Chemotherapy Agents

Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.

All agents were dosed and administered per institutional standards using the respective package insert as a guideline.

Drug: Second-Line Chemotherapy Agents

Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.

All agents were dosed and administered per institutional standards using the respective package insert as a guideline.


  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent
  • Histologically or cytologically confirmed NSCLC except for squamous cell carcinoma
  • Treated brain metastases without evidence of progression or hemorrhage after treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period
  • Appropriateness for first- or second-line systemic therapy for advanced NSCLC
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Age ≥ 18 years
  • For women of childbearing potential and sexually active males, use of an accepted and effective method of contraception (e.g., hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study

Exclusion Criteria:

  • Brain biopsy/neurosurgical procedure performed within 3 months prior to Day 1
  • Progressive neurologic symptoms
  • Active malignancy other than lung cancer
  • Current, recent, or planned participation in an experimental drug study
  • Prior treatment with an investigational or marketed agent that acts by anti-angiogenesis mechanisms
  • Gross hemoptysis within 3 months prior to Day 1
  • Inadequately controlled hypertension
  • Unstable angina or New York Heart Association Grade II or greater congestive heart failure (CHF)
  • Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1
  • Myocardial infarction within 6 months prior to Day 1
  • Stroke within 6 months prior to Day 1
  • Active symptomatic peripheral vascular disease within 6 months prior to Day 1
  • History of significant vascular disease
  • Evidence of bleeding diathesis or coagulopathy
  • Known hypersensitivity to any components of bevacizumab
  • Inadequate organ function
  • Serious non-healing wound, ulcer, or bone fracture
  • Urine protein/creatinine (UPC) ratio of ≥ 1.0
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study
  • Pregnancy or lactation
  • Known evidence of disseminated intravascular coagulation (DIC)
  • Active infection or fever > 38.5°C within 3 days prior to Day 1
  • Any other medical condition (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00312728

Sponsors and Collaborators
Genentech
Investigators
Study Director: David Karlin, M.D. Genentech
  More Information

No publications provided

Responsible Party: Jane Huang, M.D., Study Director, Genentech, Inc.
ClinicalTrials.gov Identifier: NCT00312728     History of Changes
Other Study ID Numbers: AVF3752g
Study First Received: April 7, 2006
Results First Received: March 18, 2011
Last Updated: August 3, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Genentech:
Brain Cancer
Brain Metastases
Avastin
NSCLC
Lung Cancer
PASSPORT

Additional relevant MeSH terms:
Brain Neoplasms
Neoplasms
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Neoplasm Metastasis
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Neoplastic Processes
Pathologic Processes
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 28, 2014